Nektar Therapeutics

NKTR

Market cap $2.31B

NKTR Hedge Fund Activity: Q1 2026 in Review

215 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q1 2026, worth a combined $1.92B — up 162% from $732M a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new NKTR positions and 32 closed out — a net gain of 39 holders — while 74 added to existing stakes and 48 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $239M. The largest seller was Point72 Asset Management, cutting an estimated $23.9M.

• 215 institutional investors held Nektar Therapeutics (NKTR) as of Q1 2026, up from 180 in Q4 2025.
• Funds reported $1.92B of Nektar Therapeutics stock for Q1 2026, up 162% quarter-over-quarter.
• 71 funds opened new Nektar Therapeutics positions in Q1 2026 and 32 closed out, a net change of +39 holders.
• The largest Nektar Therapeutics buyer in Q1 2026 was Fidelity Investments, an estimated $239M added.
• The largest Nektar Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $23.9M sold.

Based on aggregated 13F filings for Q1 2026.